Pfizer recorded higher other income––net (2) in second-quarter 2020 compared with other deductions––net (2) in the prior-year quarter, primarily driven by: Pfizer's effective tax rate on Reported income (2) for second-quarter 2020 compared to the prior-year quarter was negatively impacted primarily by the non-recurrence of a tax benefit recorded in second-quarter 2019 related to the settlement of a U.S. Internal Revenue Service audit for multiple tax years. Adjusted (3) Income Statement Highlights * Indicates calculation is greater than 100%. Second-quarter 2020 diluted weighted-average shares outstanding used to calculate Reported (2) and Adjusted (3) diluted EPS declined by 53 million shares compared to the prior-year quarter primarily due to Pfizer's share repurchase program, reflecting the impact of share repurchases during 2019, partially offset by shares issued for employee compensation programs.